Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia

NCT05464680 | Completed

• 2 other identifiers: RCAPHM21_0415ID-RCB
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Patients on mechanical ventilation (MV) following SARS-CoV-2 pneumonia frequently develop ventilator-associated pneumonia (VAP). The incidence of MVAP during SARS-CoV-2 infections ranges from 50 to nearly 90%. In addition, up to 80% of recurrences of VAP (a new episode, most often attributable to the same bacteria) have been described, reflecting the failure of the initial antibiotic therapy. This incidence is much higher than that described for other etiologies of acute respiratory distress syndrome (ARDS). The investigators hypothesize that during VAP, there is an alteration of the diffusion of intravenous antibiotics in the lung parenchyma in COVID-19 patients in relation to several factors characteristic of SARS-CoV-2 infection. This altered diffusion may explain the high number of recurrences of MVAP compared to non-COVID-19 patients.

Conditions

ARDS; SARS-CoV 2 Pneumonia

Keywords

mechanical ventilation; antibiotics diffusion; ARDS; SARS-CoV 2

Outcome Measures

Primary Outcomes (1)

• Compare the pulmonary diffusion of piperacillin

  Dosage in the epithelial lining fluid

  48 hours following antibiotics administration

Secondary Outcomes (5)

• Pulmonary diffusion of tazobactam

  48 hours following antibiotics administration

• Concentrations of piperacillin in effective pulmonary and plasma targets

  48 hours following antibiotics administration

• Concentrations of piperacillin in effective pulmonary and plasma targets

  7 days following antibiotics administration

• Concentrations of tazobactam in effective pulmonary and plasma targets

  7 days following antibiotics administration

• Concentrations of tazobactam in effective pulmonary and plasma targets

  48 hours following antibiotics administration

Study Arms (2)

Patients positive to SARS-CoV 2

EXPERIMENTAL

Patients admitted to the ICU and placed on VM following SARS-CoV-2 pneumonia

Other: blood sample and bronchoalveolar lavage

Patients negative to SARS-CoV 2

SHAM COMPARATOR

Patients admitted to the ICU and placed on VM outside of SARS-CoV-2 pneumonia

Other: blood sample and bronchoalveolar lavage

Interventions

blood sample and bronchoalveolar lavage OTHER

These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF. On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken. The clinical outcome of the patient will then be recorded until D60.

Patients negative to SARS-CoV 2; Patients positive to SARS-CoV 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patient over 18 years of age 2. Patient has given consent or consent obtained from the trusted person if the patient is not capable of consenting, after informed consent.
• \. Patient with ARDS 4. Patient requiring MV for ARDS (as defined by Berlin (15)), regardless of etiology (COVID-19 or other cause of ARDS) 5. Patient with suspected 1st episode of ARDS for which microbiological sampling is performed (bronchial aspiration, protected distal sampling (PDS), bronchoalveolar lavage (BAL)) 6. Patients who have received probabilistic antibiotic therapy within 24 hours of the microbiological sample, including piperacillin-tazobactam (PIP-TAZ) administered according to current recommendations.
• \. Patient who is a beneficiary of or affiliated to a social security system

You may not qualify if:

• Patients for whom PIP-TAZ is administered as a discontinuous infusion.
• Contraindication to the realization of a mini-LBA: patient whose respiratory state is too precarious for the realization of a mini-LBA for intra pulmonary antibiotics dosage (SpO2\<94% under FiO2 100% under VM), presence of a non drained pneumothorax, bronchial prosthesis, recent bronchial suture
• Patient with a second episode of PAVM.
• Patient on ExtraCorporeal Membrane Oxygenation (ECMO) or ExtraCorporeal CO2 Removal (ECCO2R).
• Pregnant or breastfeeding women, patients under guardianship or trusteeship, deprived of liberty
• Patients who are moribund or for whom limitations of active therapies have been decided.
• Any condition, which in the opinion of the investigator, would not allow the implementation of the study procedures.

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Service Médecine Intensive Réanimation

Marseille, 13015, France

Location

MeSH Terms

Interventions

Blood Specimen Collection; Bronchoalveolar Lavage

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; Therapeutic Irrigation

Study Officials

• François Cremieux

  AP-HM

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2022
• First Posted: July 19, 2022
• Study Start: November 24, 2022
• Primary Completion: May 9, 2025
• Study Completion: May 9, 2025
• Last Updated: November 19, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)